Concepedia

Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC

Amin H. Nassar, Ritujith Jayakrishnan, Jamie Feng, Frances A. Shepherd, Elio Adib, Justin M. Cheung, Yufei Liu, Steven H. Lin, Kaushal Parikh, Arthi Sridhar,

Journal of Thoracic Oncology · 2024 · 14 citations · 22 references

DOIFull text

Open access

Concepts

References

22

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

Manabu Soda, Young Lim Choi, Munehiro Enomoto et al. · Nature · 2007 · 5.4K citations

, , +14

First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer

Benjamin Solomon, Tony Mok, Dong‐Wan Kim et al. · New England Journal of Medicine · 2014 · 3.2K citations · Full text

, , +12

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

, , +17

Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer

Solange Peters, D. Ross Camidge, Alice T. Shaw et al. · New England Journal of Medicine · 2017 · 2.5K citations · Full text

, , +16

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i>

Alice T. Shaw, Beow Y. Yeap, Mari Mino–Kenudson et al. · Journal of Clinical Oncology · 2009 · 1.9K citations · Full text

, , +17